CY1119790T1 - Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας - Google Patents
Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακαςInfo
- Publication number
- CY1119790T1 CY1119790T1 CY20181100065T CY181100065T CY1119790T1 CY 1119790 T1 CY1119790 T1 CY 1119790T1 CY 20181100065 T CY20181100065 T CY 20181100065T CY 181100065 T CY181100065 T CY 181100065T CY 1119790 T1 CY1119790 T1 CY 1119790T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- cladrivin
- therapeutic
- multiple sclerosis
- cladribine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται στη χρήση της Κλαδριβίνης για τη παρασκευή ενός φαρμακευτικού σκευάσματος για την θεραπευτική αντιμετώπιση της σκλήρυνσης κατά πλάκας, συγκεκριμένα της υποτροπιάζουσας - διαλείπουσας σκλήρυνσης κατά πλάκας ή της πρώιμης δευτερογενούς προϊούσας σκλήρυνσης κατά πλάκας, η οποία παρασκευή πρόκειται να χορηγηθεί από το στόμα και όπου επαναληπτικές θεραπείες είναι πιθανές.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| EP05823474A EP1827461B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
| EP10182676.6A EP2263678B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating early secondary progressive Multiple Sclerosis |
| EP14001970.4A EP2805723B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119790T1 true CY1119790T1 (el) | 2018-06-27 |
Family
ID=36227798
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100358T CY1112614T1 (el) | 2004-12-22 | 2012-04-11 | Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης |
| CY20181100065T CY1119790T1 (el) | 2004-12-22 | 2018-01-18 | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας |
| CY2018006C CY2018006I2 (el) | 2004-12-22 | 2018-02-28 | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100358T CY1112614T1 (el) | 2004-12-22 | 2012-04-11 | Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2018006C CY2018006I2 (el) | 2004-12-22 | 2018-02-28 | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (el) |
| EP (6) | EP2275110B1 (el) |
| JP (7) | JP5795456B2 (el) |
| KR (1) | KR20070091662A (el) |
| AR (1) | AR052830A1 (el) |
| AU (2) | AU2005318190B2 (el) |
| BR (1) | BRPI0517132B8 (el) |
| CA (2) | CA3087419C (el) |
| CY (3) | CY1112614T1 (el) |
| DK (3) | DK3332789T3 (el) |
| EA (1) | EA015799B1 (el) |
| ES (1) | ES2921858T3 (el) |
| FI (1) | FI4070800T3 (el) |
| FR (1) | FR18C1008I2 (el) |
| HR (1) | HRP20120228T1 (el) |
| HU (2) | HUE059133T2 (el) |
| IL (2) | IL183930A0 (el) |
| LT (3) | LT3332789T (el) |
| LU (1) | LUC00064I2 (el) |
| MX (1) | MX2007007610A (el) |
| NO (1) | NO20073813L (el) |
| PL (3) | PL3332789T3 (el) |
| SG (1) | SG160391A1 (el) |
| SI (2) | SI2805723T1 (el) |
| WO (1) | WO2006067141A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090019810A (ko) | 2006-05-24 | 2009-02-25 | 라보라뚜와르 세로노 에스. 에이. | 다발성 경화증 치료를 위한 클라드리빈 요법 |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| KR102743999B1 (ko) | 2017-11-24 | 2024-12-17 | 메르크 파텐트 게엠베하 | 진행 형태의 다발성 경화증의 치료에서 사용을 위한 클라드리빈 용법 |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| ES2182920T3 (es) | 1994-12-22 | 2003-03-16 | Ortho Pharma Corp | Formulaciones solubles de 2-cloro02'-deoxiadenosina. |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| US7572909B2 (en) | 2002-09-25 | 2009-08-11 | Brigham Young University | Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| CN1761471A (zh) * | 2003-02-25 | 2006-04-19 | 应用研究系统Ars股份公司 | 利巴韦林与干扰素β在脱髓鞘疾病中的联用 |
| MEP34508A (en) | 2003-03-28 | 2011-02-10 | Ares Trading Sa | Cladribine formulations for improved oral and transmucosal delivery |
| AU2004226437B2 (en) | 2003-03-28 | 2010-06-03 | Ares Trading S.A. | Oral formulations of cladribine |
| KR20090019810A (ko) * | 2006-05-24 | 2009-02-25 | 라보라뚜와르 세로노 에스. 에이. | 다발성 경화증 치료를 위한 클라드리빈 요법 |
-
2005
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Application Discontinuation
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es active Active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja active Active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en active Active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-03-13 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119790T1 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
| CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
| CY1123050T1 (el) | Φαρμακα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων | |
| CY1107084T1 (el) | Παραγωγα πυρρολοπυριδαζινης | |
| CY1121134T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης | |
| CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
| CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| NO20055894L (no) | Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer | |
| CY1113394T1 (el) | Αντισωματα toy pan-kir2dl νκ υποδοχεα και η χρηση τους στη διαγνωση και τη θεραπεια | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| CY1113167T1 (el) | Ανθρωπινα anti-ngf εξουδετερωτικα αντισωματα ως εκλεκτικοι αναστολεις μονοπατιου ngf | |
| CY1109229T1 (el) | Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο | |
| CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
| CY1122549T1 (el) | Παραγωγα καρβαζολης | |
| MXPA05011208A (es) | Uso de ivermectina para el tratamiento de desordenes dermatologicos. | |
| EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| CY1109045T1 (el) | Ρετινοειδη για τη θεραπεια του εμφυσηματος | |
| CY1116494T1 (el) | Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| CY1105317T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων |